Compounds with hydroxycarbonyl-halogenoalkyl side chain
    1.
    发明授权
    Compounds with hydroxycarbonyl-halogenoalkyl side chain 失效
    具有羟基羰基 - 卤代烷基侧链的化合物

    公开(公告)号:US06737417B2

    公开(公告)日:2004-05-18

    申请号:US10149752

    申请日:2002-06-13

    IPC分类号: C07J100

    摘要: The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1 represents a hydrogen atom, etc., R2 represents a C1-C7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

    摘要翻译: 本发明提供由部分和化学键合到所述部分的基团组成的化合物,其中所述部分含有口服后具有低活性的化合物或其母体支架,并且所述基团具有以下通式(1):其中R 1表示 氢原子等,R2表示C1-C7卤代烷基等,m表示2〜14的整数,n表示2〜7的整数,或该化合物的对映异构体或其水合物或药学上可接受的盐 其化合物或其对映异构体。 上述化合物在药物用途中是有利的,因为通式(1)的基团允许化合物如抗雌激素的化合物在连接到化合物的母体支架上时在口服给药后显示出显着增加的活性。

    Compounds with hydroxycarbonyl-halogenoalkyl side chains
    3.
    发明申请
    Compounds with hydroxycarbonyl-halogenoalkyl side chains 审中-公开
    具有羟基羰基 - 卤代烷基侧链的化合物

    公开(公告)号:US20050192449A1

    公开(公告)日:2005-09-01

    申请号:US11115134

    申请日:2005-04-27

    摘要: The present invention provides a compound consisting of a moiety and a group chemically bonded to said moiety, wherein said moiety contains a compound having low activity following oral administration or its parent scaffold and said group has the following general formula (1): in which R1 represents a hydrogen atom, etc., R2 represents a C1-C7 halogenoalkyl group, etc., m represents an integer of 2 to 14, and n represents an integer of 2 to 7, or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or enantiomers thereof. The above compound is advantageous in pharmaceutical use because the group of general formula (1) allows compounds such as anti-estrogenic ones to show a significantly increased activity following oral administration when attached to the parent scaffolds of the compounds.

    摘要翻译: 本发明提供了由部分和化学键合到所述部分的基团组成的化合物,其中所述部分含有口服后具有低活性的化合物或其母体支架,所述基团具有以下通式(1):其中R R 1表示氢原子等,R 2表示C 1 -C 7卤代烷基等 m表示2〜14的整数,n表示2〜7的整数,或该化合物的对映异构体,或其化合物或其对映异构体的水合物或药学上可接受的盐。 上述化合物在药物用途中是有利的,因为通式(1)的基团允许化合物如抗雌激素的化合物在连接到化合物的母体支架上时在口服给药后显示出显着增加的活性。

    3-methyl-chroman and -thiochroman derivatives
    7.
    发明授权
    3-methyl-chroman and -thiochroman derivatives 失效
    3-甲基 - 苯并二氢吡喃并 - 二氢苯并噻喃衍生物

    公开(公告)号:US06552069B1

    公开(公告)日:2003-04-22

    申请号:US10149751

    申请日:2002-06-13

    IPC分类号: A61K3138

    CPC分类号: C07D335/06 C07D311/58

    摘要: The present invention provides a compound having the following general formula (1): in which R1 represents a hydrogen atom, etc.; R2 represents a C3-C3 perhalogenoalkyl group, etc.; each of R3 and R4 independently represents a hydrogen atom, etc.; X represents an oxygen atom or a sulfur atom; m represents an integer of 2 to 14; and n represents an integer of 0 to 8; or enantiomers of the compound, or hydrates or pharmaceutically acceptable salts of the compound or its enantiomers. The compound of general formula (1) is advantageous in pharmaceutical use because of its anti-estrogenic activity.

    摘要翻译: 本发明提供具有以下通式(1)的化合物:其中R 1表示氢原子等; R 2表示C 3 -C 3全卤代烷基等; R 3和R 4各自独立地表示氢原子等。 X表示氧原子或硫原子,m表示2〜14的整数, 和n表示0至8的整数;或化合物的对映异构体,或化合物或其对映异构体的水合物或药学上可接受的盐。 通式(1)的化合物由于其抗雌激素活性而在药物应用中是有利的。

    Benzopyran derivatives
    10.
    发明授权
    Benzopyran derivatives 有权
    苯并吡喃衍生物

    公开(公告)号:US6153768A

    公开(公告)日:2000-11-28

    申请号:US319616

    申请日:1999-06-08

    摘要: The present invention relates to a novel benzopyran derivative having anti-estrogenic activity. More specifically, the present invention relates to a novel benzopyran derivative represented by formula (I) and pharmaceutically acceptable salt thereof, in which ----- represents a single bond or a double bond; R1 and R2 independently of one another represent hydrogen, hydroxy or OR group, wherein R represents acyl or alkyl; R3 represents hydrogen, lower alkyl or halogeno lower alkyl, provided that when ----- represents a double bond, R3 is not present; R4 represents hydrogen or lower alkyl; A represents a group of formula a, b, c or d; R5, R6 and R7 independently of one another represent hydrogen, alkyl, halogenoalkyl, alkenyl or halogenoalkenyl, or R6 and R7 together with nitrogen atom to which they are bound can form a 4- to 8-membered heterocyclic ring which can be substituted with R5; X represents O, S, or NR8, wherein R8 represents hydrogen or lower alkyl; m denotes an integer of 2 to 15; n denotes an integer of 0 to 2; and p denotes an integer of 0 to 4.

    摘要翻译: PCT No.PCT / KR97 / 00265 Sec。 371 1999年6月8日第 102(e)日期1999年6月8日PCT 1997年12月13日PCT公布。 公开号WO98 / 25916 PCT 日期:1998年6月18日本发明涉及具有抗雌激素活性的新型苯并吡喃衍生物。 更具体地说,本发明涉及由式(I)表示的新型苯并吡喃衍生物及其药学上可接受的盐,其中+ E,uns ----- + EE表示单键或双键; R 1和R 2彼此独立地表示氢,羟基或OR基,其中R表示酰基或烷基; R3表示氢,低级烷基或卤代低级烷基,条件是当+ E时,不为 - + EE表示双键,R3不存在; R4代表氢或低级烷基; A表示式a,b,c或d的基团; R 5,R 6和R 7彼此独立地表示氢,烷基,卤代烷基,烯基或卤代烯基,或者R 6和R 7与它们所连接的氮原子一起可以形成可被R 5取代的4至8元杂环 ; X表示O,S或NR8,其中R8表示氢或低级烷基; m表示2〜15的整数, n表示0〜2的整数, p表示0〜4的整数。